Skip to main content
Remicade Patient Reminder Card
This patient reminder card contains important safety information that you need to be aware of before and during treatment with Remicade.
Back to top
Risk Minimisation Materials
Search by company, common medicine name, or title of Risk Minimisation Material
Remicade
Janssen-Cilag Ltd (a Johnson & Johnson Company)
Remsima
Celltrion Healthcare UK Limited
Replagal
Takeda UK Ltd
Healthcare Professional (HCP) Guide for Self-administration/Home Infusion of Replagal®
For Healthcare Professionals
Replagal HCP Guide
Revlimid
Bristol Myers Squibb Pharmaceuticals limited
Revlimid® (lenalidomide) Algorithm
For Healthcare Professionals
This Algorithm provides high level steps for prescribing and dispensing of lenalidomide.
Revlimid® (lenalidomide) Frequently Asked Questions
For Healthcare Professionals
The FAQs (Frequently Asked Questions) provides answers to common questions that healthcare professionals may have about the medication.
Revlimid® (lenalidomide) Healthcare Professional’s Information Pack
For Healthcare Professionals
This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense lenalidomide. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient.
Revlimid® (lenalidomide) Information for Healthcare Professionals
For Healthcare Professionals
This brochure contains the information needed for prescribing and dispensing of lenalidomide, including information about the Pregnancy Prevention Programme. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.
Revlimid® (lenalidomide) Information for Patients
This brochure should be given to patients receiving treatment with lenalidomide, as it provides important information about the lenalidomide Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking lenalidomide and how to report side effects.
Revlimid® (lenalidomide) Male Risk Awareness Form
For Healthcare Professionals
This Risk Awareness Form must be completed for each male patient prior to the initiation of their lenalidomide treatment. It is mandatory that male patients receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
Revlimid® (lenalidomide) Patient Pocket Information Card
This card should be given to all patient as it reminds patients of the key educational information and risks of treatment with lenalidomide.
Revlimid® (lenalidomide) Pharmacy Registration Form
For Healthcare Professionals
This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense lenalidomide. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of lenalidomide will only be allowed from pharmacies registered with BMS.
Revlimid® (lenalidomide) Prescription Authorisation Form
For Healthcare Professionals
A newly completed Prescription Authorisation Form must accompany each lenalidomide prescription to confirm that the patient has been counselled about the teratogenic risk of lenalidomide and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.
Revlimid® (lenalidomide) Woman of Childbearing Potential Risk Awareness Form
For Healthcare Professionals
This Risk Awareness Form must be completed for each woman of childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
Revlimid® (lenalidomide) Woman of Non-Childbearing Potential Risk Awareness Form
For Healthcare Professionals
This Risk Awareness Form must be completed for each woman of non-childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.
Rimmyrah
Orion Pharma (UK) Limited
Rimmyrah CNV educational materials
Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia
Rimmyrah nAMD educational materials
Important safety information for patients treated with: RIMMYRAH (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD)
Rimmyrah PDR/DMO educational materials
Important safety information for patients treated with:
RIMMYRAH (ranibizumab) with proliferative diabetic retinopathy
(PDR) and/or visual impairment due to diabetic macular oedema (DMO)
Rimmyrah RVO educational materials
Important safety information for patients treated with:
RIMMYRAH (ranibizumab) with visual impairment due to retinal vein occlusion (RVO)
Rinvoq
AbbVie Ltd
Rivaroxaban
Amarox Limited
Aspire Pharma Ltd
Rivaroxaban Prescriber Guide for HealthCare Professionals
For Healthcare Professionals
Rivaroxaban Prescriber Guide for HealthCare Professionals
Brown & Burk UK Ltd
Celix Pharma Ltd
Dr. Reddy's Laboratories (UK) Ltd
Gedeon Richter (UK) Ltd
Rivaroxaban Patient Alert Card
Rivaroxaban Patient Alert Card - Provided to each patient who is prescribed Rivaroxaban Gedeon Richter film coated tablets to inform treating physicians and dentists about the patient‘s anticoagulation treatment.
Rivaroxaban Prescriber Guide
For Healthcare Professionals
Rivaroxaban Prescriber Guide - The Prescriber Guide provides recommendations for the use of Rivaroxaban in order to minimise the risk of bleeding during treatment with Rivaroxaban.
Genus Pharmaceuticals
Rivaroxaban - Patient Alert Card
Patient alert card for Rivaroxaban – noting patient’s anticoagulation treatment
Glenmark Pharmaceuticals Europe Ltd
Rivaroxaban Patient Alert Card 2.5 mg
Information on anticoagulation treatment with Rivaroxaban film-coated tablets
Rivaroxaban Prescriber Guide
For Healthcare Professionals
Important risk minimisation information for healthcare professionals
Rivaroxaban Prescriber Guide 2.5 mg
For Healthcare Professionals
Important risk minimization information for healthcare professionals
Krka UK Ltd
Rivaroxaban Prescriber Guide
For Healthcare Professionals
This guide is to be used to support the appropriate use of Rivaroxaban. It includes the following information: • Dosing recommendations • Oral intake • Perioperative management • Contraindications • Overdose • How to manage bleeding complications • Coagulation testing
Laboratorios Liconsa, S.A.
MSN Laboratories Europe Ltd
Mylan
Ranbaxy (UK) Limited a Sun Pharmaceutical Company
Sandoz Limited
Rivaroxaban Patient Alert Card ( 10, 15 and 20mg)
A patient alert card is provided with the product package to each patient who is prescribed Rivaroxaban. Prescribers are to explain the implications of anticoagulant treatment to patients and/or caregiver, in particular highlighting the need for:
• Treatment compliance
• Recognising signs or symptoms of bleeding
• When to seek medical attention
• The need to inform HCPs that they are taking rivaroxaban if they need to have any surgery or invasive procedure.
The patient alert card will inform treating physicians and dentists about the patient‘s anticoagulation treatment and will contain emergency contact information.
Rivaroxaban Patient Alert Card (2.5 mg)
A patient alert card is provided with the product package to each patient who is prescribed Rivaroxaban. Prescribers are to explain the implications of anticoagulant treatment to patients and/or caregiver, in particular highlighting the need for:
• Treatment compliance
• Recognising signs or symptoms of bleeding
• When to seek medical attention
• The need to inform HCPs that they are taking rivaroxaban if they need to have any surgery or invasive procedure.
The patient alert card will inform treating physicians and dentists about the patient‘s anticoagulation treatment and will contain emergency contact information.
Rivaroxaban Prescriber Guide
For Healthcare Professionals
This guide is to be used to support the appropriate use of Rivaroxaban.
It includes the following information:
• Dosing recommendations
• Oral intake
• Perioperative management
• Contraindications
• Overdose
• How to manage bleeding complications
• Coagulation testing
Teva UK Limited
Wockhardt UK Ltd
Zentiva
Rivaroxaban Patient Alert Card - 2.5mg, 10mg, 15mg, 20mg
Rivaroxaban Patient Alert Card - 2.5mg, 10mg, 15mg, 20mg
RIVAROXABAN PRESCRIBER GUIDE
For Healthcare Professionals
Prescriber Guide for tablets and oral suspension
Rivastigmine Luye
Luye Pharma Limited
Rixathon
Sandoz Limited
Rixathon (rituximab) - IV administration only
For Healthcare Professionals
A healthcare professional card highlighting the route of administration for Rixathon Healthcare Professional
Rixathon (rituximab) Healthcare Professional Educational Leaflet - Important safety information for healthcare professionals in treating patients with Rixathon therapy
For Healthcare Professionals
This guide is intended to review key facts and important safety information about rituximab in non-oncology diseases and to provide important patient counselling information to assist healthcare professionals in caring for patients receiving rituximab therapy.
Rixathon (rituximab) Patient Educational Leaflet - Important safety information for patients receiving Rixathon therapy
The information provided in this booklet should be discussed with patients by their healthcare professional during Rixathon(rituximab) treatment.
Roaccutane
Neon Healthcare Ltd
Isotretinoin Acknowledgement of Risk Form
Acknowledgement Form for Prescribing Isotretinoin to Female Patients.
Patient Reminder Card for Isotretinoin
Patient Reminder Card for Isotretinoin containing Important Reminders for Patients
Pharmacist Checklist Guidance for Dispensing Oral Isotretinoin
For Healthcare Professionals
Guidance for the Pharmacist when Dispensing Oral Isotretinoin
Roche Products Limited
Roaccutane (oral isotretinoin) Acknowledgement of Risk Form
For Healthcare Professionals
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan
Roaccutane (oral isotretinoin) Patient Reminder Card
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan
Roaccutane (oral isotretinoin) Pharmacist Checklist
For Healthcare Professionals
This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan.
RoActemra
Roche Products Limited
RoActemra (tocilizumab) Healthcare Professional Brochure
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
RoActemra (tocilizumab) Important Safety Information for Patients
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
RoActemra (tocilizumab) Patient Card
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
RoActemra Dosing Guide for RoActemra (tocilizumab) intravenous (IV) and subcutaneous (SC) formulations
For Healthcare Professionals
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
Ruconest
Pharming Group N.V.
HCP instructions - Immunological Assessments
For Healthcare Professionals
Non-promotional educational materials of Immunological Assessments for the Healthcare Professional
Ruxience
Pfizer Limited
Ruxience Healthcare professional guide
For Healthcare Professionals
Provides guidance on the route of administration (intravenous only), management, monitoring and safety considerations related to the risk management plan.
Ruxience Patient Alert Card
Provides help to patients to understand the risks associated with Ruxience and reminds them to seek immediate medical attention if they experience any of the listed signs and symptoms.
Ruxience Patient Brochure
Provides information to patients on the risks, signs and symptoms of infection and the need to contact their doctor immediately if they experience them.
Rybrevant
Janssen-Cilag Ltd (a Johnson & Johnson Company)
Rybrevant -Important Risk Minimisation Information-Guide to Dosing and Administration
For Healthcare Professionals
Guide to intravenous dosing and administration. Important risk minimisation information.
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
